Propeller Health

propellerhealth.com

Propeller Health is a leading digital therapeutics company dedicated to the development and commercialization of measurably better medicines. Propeller creates products to more effectively treat disease and improve clinical outcomes for patients across a range of therapeutic areas through connectivity, analytics, and companion digital experiences. The Propeller platform is used by patients, physicians and healthcare organizations in the US, Europe and Asia.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharma Tech

BENCHSCI NAMED A DELOITTE TECHNOLOGY FAST 50™ COMPANY AS IMPACT ON DRUG DISCOVERY GROWS

BenchSci, Deloitte Technology Fast 50™ | November 23, 2021

news image

BenchSci, an emerging global leader in machine learning applications for novel medicine development, announced it ranks 19th among the country’s fastest-growing technology companies in the Deloitte Technology Fast 50™. The program awards companies for their rapid revenue growth, entrepreneurial spirit, and bold innovation, and consists of public and private companies in the tech sector which have transformed the industry. “ Read More

UROGEN PHARMA ANNOUNCES INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)

Business Wire | March 06, 2020

news image

UroGen Pharma Ltd. a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options, today announced the grants of inducement restricted stock units (“RSUs”) to seventy-six new employees in connection with their employment with Urogen. These new team members will support the Company as it prepares for potential approval and commercial launch of its first product candidate....

Read More

Business Insights

KEMPHARM ANNOUNCES STRATEGIC ACQUISITION OF ARIMOCLOMOL FROM ORPHAZYME, EXPANDING ITS RARE CNS DISEASES PIPELINE

KemPharm | May 16, 2022

news image

Arimoclomol is an NDA-stage, revenue-generating investigational drug candidate being developed for the treatment of Niemann-Pick disease type C a rare progressive neurodegenerative disease KemPharm plans to refile the New Drug Application (NDA) for arimoclomol in NPC with the U.S. Food and Drug Administration as early as the First Quarter of 2023 CELEBRATION, Fla., May 15, 2022 KemPharm, Inc. a specialty pharmaceutical company focused on the discovery and developmen...

Read More

Business Insights

ACURX PHARMACEUTICALS TO JOIN THE RUSSELL MICROCAP INDEX®

Acurx Pharmaceuticals, Inc. | September 06, 2021

news image

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company is set to join the Russell Microcap® Index when the market opens on September 20, 2021, according to a preliminary list of additions posted on September 1, 2021. Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate gr...

Read More
news image

Pharma Tech

BENCHSCI NAMED A DELOITTE TECHNOLOGY FAST 50™ COMPANY AS IMPACT ON DRUG DISCOVERY GROWS

BenchSci, Deloitte Technology Fast 50™ | November 23, 2021

BenchSci, an emerging global leader in machine learning applications for novel medicine development, announced it ranks 19th among the country’s fastest-growing technology companies in the Deloitte Technology Fast 50™. The program awards companies for their rapid revenue growth, entrepreneurial spirit, and bold innovation, and consists of public and private companies in the tech sector which have transformed the industry. “ Read More

news image

UROGEN PHARMA ANNOUNCES INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)

Business Wire | March 06, 2020

UroGen Pharma Ltd. a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options, today announced the grants of inducement restricted stock units (“RSUs”) to seventy-six new employees in connection with their employment with Urogen. These new team members will support the Company as it prepares for potential approval and commercial launch of its first product candidate....

Read More
news image

Business Insights

KEMPHARM ANNOUNCES STRATEGIC ACQUISITION OF ARIMOCLOMOL FROM ORPHAZYME, EXPANDING ITS RARE CNS DISEASES PIPELINE

KemPharm | May 16, 2022

Arimoclomol is an NDA-stage, revenue-generating investigational drug candidate being developed for the treatment of Niemann-Pick disease type C a rare progressive neurodegenerative disease KemPharm plans to refile the New Drug Application (NDA) for arimoclomol in NPC with the U.S. Food and Drug Administration as early as the First Quarter of 2023 CELEBRATION, Fla., May 15, 2022 KemPharm, Inc. a specialty pharmaceutical company focused on the discovery and developmen...

Read More
news image

Business Insights

ACURX PHARMACEUTICALS TO JOIN THE RUSSELL MICROCAP INDEX®

Acurx Pharmaceuticals, Inc. | September 06, 2021

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company is set to join the Russell Microcap® Index when the market opens on September 20, 2021, according to a preliminary list of additions posted on September 1, 2021. Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate gr...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us